Nouscom raises €120 million in oversubscribed Series D financing
Proceeds advance NOUS209, its off-the-shelf cancer interception immunotherapy, into a global pivotal trial for Lynch Syndrome carriers, which holds FDA Fast Track designation.
See the latest news and media coverage for Nouscom. We track all announcements, press releases, and industry mentions in real time, all in one place.
Cancer immunotherapy biotechnology company
nouscom.comLast updated
In short: Nouscom raised €120 million to advance NOUS-209 into a global pivotal Lynch syndrome trial.
Proceeds advance NOUS209, its off-the-shelf cancer interception immunotherapy, into a global pivotal trial for Lynch Syndrome carriers, which holds FDA Fast Track designation.
All evaluable Lynch syndrome carriers remained free of advanced adenomas and colorectal cancer through year two, and Nouscom plans a global pivotal trial.
The immunotherapy was well tolerated, induced durable T cell responses and reduced precancer lesions in carriers, with no new advanced adenomas one year after treatment.
The immunotherapy combined with pembrolizumab achieved a 15% objective response rate and 70% disease control rate in patients refractory to anti-PD-1 therapy.
Promotion follows recent €120 million Series D financing as Nouscom advances NOUS-209 into registration-enabling trial in Lynch Syndrome and prepares for commercial-scale manufacturing BASEL, ...
An investor syndicate co-led by M Ventures and Revelation Partners has bet on the program. (iStock / Getty Images Plus) Nouscom has reeled in 120...
Nous-209 has been developed using the Nouscom's viral vector platform, which includes adenoviral and Modified Vaccinia Ankara (MVA) vectors, with MVA vectors manufactured using ProBioGen's...
While immune checkpoint inhibitors (anti-PD-1 +/- anti-CTLA-4) are approved as first line treatment for microsatellite instability-high (MSI-H) metastatic colorectal cancer (mCRC), many patients either don't...
Track Nouscom and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Nouscom and other trending companies.